Detalles de la búsqueda
1.
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Ann Hematol
; 102(1): 63-72, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399194
2.
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Br J Haematol
; 192(6): e148-e151, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33618424
3.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Blood Adv
; 6(12): 3684-3696, 2022 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35468621
4.
Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.
Cancers (Basel)
; 13(23)2021 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34884988
5.
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Cancers (Basel)
; 13(11)2021 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34200318
6.
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
Eur J Cancer
; 150: 143-154, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33901793
7.
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
Cancers (Basel)
; 12(12)2020 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33256235
8.
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Cancers (Basel)
; 12(6)2020 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32517329
Resultados
1 -
8
de 8
1
Próxima >
>>